PART 201—LABELING
- § 201.1 - Drugs; name and place of business of manufacturer, packer, or distributor.
- § 201.2 - Drugs and devices; National Drug Code numbers.
- § 201.5 - Drugs; adequate directions for use.
- § 201.6 - Drugs; misleading statements.
- § 201.10 - Drugs; statement of ingredients.
- § 201.15 - Drugs; prominence of required label statements.
- § 201.16 - Drugs; Spanish-language version of certain required statements.
- § 201.17 - Drugs; location of expiration date.
- § 201.18 - Drugs; significance of control numbers.
- § 201.19 - Drugs; use of term “infant”.
- § 201.20 - Declaration of presence of FD&C Yellow No. 5 and/or FD&C Yellow No. 6 in certain drugs for human use.
- § 201.21 - Declaration of presence of phenylalanine as a component of aspartame in over-the-counter and prescription drugs for human use.
- § 201.22 - Prescription drugs containing sulfites; required warning statements.
- § 201.23 - Required pediatric studies.
- § 201.24 - Labeling for systemic antibacterial drug products.
- § 201.25 - Bar code label requirements.
- § 201.26 - Exceptions or alternatives to labeling requirements for human drug products held by the Strategic National Stockpile.
- § 201.50 - Statement of identity.
- § 201.51 - Declaration of net quantity of contents.
- § 201.55 - Statement of dosage.
- § 201.56 - Requirements on content and format of labeling for human prescription drug and biological products.
- § 201.57 - Specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(b)(1).
- § 201.58 - Waiver of labeling requirements.
- § 201.60 - Principal display panel.
- § 201.61 - Statement of identity.
- § 201.62 - Declaration of net quantity of contents.
- § 201.63 - Pregnancy/breast-feeding warning.
- § 201.64 - Sodium labeling.
- § 201.66 - Format and content requirements for over-the-counter (OTC) drug product labeling.
- § 201.70 - Calcium labeling.
- § 201.71 - Magnesium labeling.
- § 201.72 - Potassium labeling.
- § 201.80 - Specific requirements on content and format of labeling for human prescription drug and biological products; older drugs not described in § 201.56(b)(1).
- § 201.100 - Prescription drugs for human use.
- § 201.105 - Veterinary drugs.
- § 201.115 - New drugs or new animal drugs.
- § 201.116 - Drugs having commonly known directions.
- § 201.117 - Inactive ingredients.
- § 201.119 - In vitro diagnostic products.
- § 201.120 - Prescription chemicals and other prescription components.
- § 201.122 - Drugs for processing, repacking, or manufacturing.
- § 201.125 - Drugs for use in teaching, law enforcement, research, and analysis.
- § 201.127 - Drugs; expiration of exemptions.
- § 201.128 - Meaning of “intended uses”.
- § 201.128 - Meaning of “intended uses”.
- § 201.129 - Drugs; exemption for radioactive drugs for research use.
- § 201.150 - Drugs; processing, labeling, or repacking.
- § 201.161 - Medical gases.
- § 201.200 - Disclosure of drug efficacy study evaluations in labeling and advertising.
- § 201.300 - Notice to manufacturers, packers, and distributors of glandular preparations.
- § 201.301 - Notice to manufacturers, packers, and distributors of estrogenic hormone preparations.
- § 201.302 - Notice to manufacturers, packers, and distributors of drugs for internal use which contain mineral oil.
- § 201.303 - Labeling of drug preparations containing significant proportions of wintergreen oil.
- § 201.304 - Tannic acid and barium enema preparations.
- § 201.305 - Isoproterenol inhalation preparations (pressurized aerosols, nebulizers, powders) for human use; warnings.
- § 201.306 - Potassium salt preparations intended for oral ingestion by man.
- § 201.307 - Sodium phosphates; package size limitation, warnings, and directions for over-the-counter sale.
- § 201.308 - Ipecac syrup; warnings and directions for use for over-the-counter sale.
- § 201.309 - Acetophenetidin (phenacetin)-containing preparations; necessary warning statement.
- § 201.310 - Phenindione; labeling of drug preparations intended for use by man.
- § 201.311 - Magnesium sulfate heptahy-drate; label declaration on drug products.
- § 201.312 - Magnesium sulfate heptahy-drate; label declaration on drug products.
- § 201.313 - Estradiol labeling.
- § 201.314 - Labeling of drug preparations containing salicylates.
- § 201.315 - Over-the-counter drugs for minor sore throats; suggested warning.
- § 201.316 - Drugs with thyroid hormone activity for human use; required warning.
- § 201.317 - Digitalis and related cardiotonic drugs for human use in oral dosage forms; required warning.
- § 201.319 - Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids (including, but not limited to agar, alginic acid, calcium polycarbophil, carboxymethylcellulose sodium, carrageenan, chondrus, glucomannan ((B-1,4 linked) polymannose acetate), guar gum, karaya gum, kelp, methylcellulose, plantago seed (psyllium), polycarbophil tragacanth, and xanthan gum) as active ingredients; required warnings and directions.
- § 201.320 - Warning statements for drug products containing or manufactured with chlorofluorocarbons or other ozone-depleting substances.
- § 201.323 - Aluminum in large and small volume parenterals used in total parenteral nutrition.
- § 201.325 - Over-the-counter drugs for vaginal contraceptive and spermicide use containing nonoxynol 9 as the active ingredient; required warnings and labeling information.
- § 201.326 - Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required warnings and other labeling.
- § 201.327 - Over-the-counter sunscreen drug products; required labeling based on effectiveness testing.
- § 201.328 - Labeling of medical gas containers.
